Salute e Benessere

GCC Sanitary Ware Market to Reach $1,303.5 Million, by 2032 at 6.4% CAGR: Allied…

Download Sample Copy of Report: https://www.alliedmarketresearch.com/request-sample/290649 Download Sample Copy of Report:https://www.alliedmarketresearch.com/request-sample/290649 Prime determinants of growth The GCC sanitary ware market includes both bathroom and kitchen fixtures, serving as an essential component of the construction and interior design industry. The GCC sanitary ware market includes a broad range of products designed for bathrooms, and kitchens. It...
PR Newswire
11/01/2024

Boehringer expands production site in Greece for new medicine

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications. Main disease areas include cardio-renal-metabolic (CRM) diseases, mental health, pulmonary fibrosis, systemic sclerosis, and chronic liver disease, some of them in the late-stage development of the company's strong...
Nasdaq GlobeNewswire
11/01/2024

Breast Implants Market Predicted to Reach USD 58.2 Billion by 2035 Says, Roots…

Global Breast Implants Market Overview Global Breast Implants Market Overview The global breast implants market is estimated to be worth USD 19.2 billionin 2023and is anticipated to reach USD 58.2 billionby 2035. It is expected to grow at a compounded annual growth rate (CAGR) of9.67%during the forecast period from2023 to 2035. The growth of breast implants market is likely to be the result of increasing demand for cosmetic procedures to improve physical...
PR Newswire
11/01/2024

Cell Line Characterization and Cell Line Development Market Growing at a CAGR of…

The global cell line characterization and cell line development market is growing rapidly. The cell line characterization (CLC) market size is estimated to be worth USD 0.8 billion in 2023 and expected to reach USD 3.8 billion by 2035. Further, the cell line development (CDC) market size is expected to be worth USD 1.0 billion in 2023 and is anticipated to reach USD 4.5 billion by 2035. The CLC market will grow at a compounded annual growth rate (CAGR) of 13.3% and the CLD market will grow at a…
PR Newswire
11/01/2024

Recommendation by the Orion Nomination Committee on the proposals to be…

ORION CORPORATIONSTOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 11 JANUARY 2024 at 16.50 EET Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General MeetingThe Nomination Committee of Orion Corporation has on 11 January 2024 given to the company's Board of Directors its recommendation on the proposal to the Annual General Meeting of 2024 concerning the composition of...
Nasdaq GlobeNewswire
11/01/2024

PulseAI's Groundbreaking AI Algorithm Enhances Consumer ECG Diagnostics

The study was conducted by a team of cardiologists and researchers at the University Hospital Basel, Switzerland. The results demonstrate that PulseAI's neural network algorithm significantly reduces inconclusive diagnoses from commercially available consumer ECG devices by Apple, Samsung, AliveCor and Fitbit. This innovation enhances the accuracy of atrial fibrillation (AF) detection, a leading precursor to stroke, improving specificity and sensitivity compared to existing algorithms from each…
PR Newswire
11/01/2024

Insurance portfolio of Orion Pension Fund's B fund transferred to an external…

ORION CORPORATIONSTOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE11 JANUARY 2024 at 14.15 EET Insurance portfolio of Orion Pension Fund's B fund transferred to an external pension insurance company – the transfer has approximately EUR 31 million positive impact on Orion's result in 2023 The insurance portfolio of the Orion Pension Fund's B fund has been transferred to pension insurance company Elo on 31 December 2023. The transfer...
Nasdaq GlobeNewswire
11/01/2024

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

"The increasing global adoption of SMILE from ZEISS represents the positive impact the small incision lenticule extraction procedure continues to have on the quality of life for patients," said Andrew Chang, Head of Global Sales for ZEISS Medical Technology. "With the availability of the ZEISS SMILE pro software module in the U.S. market, surgeons can now offer the latest refractive technology to help expand their business and provide excellent outcomes for patients."…
PR Newswire
11/01/2024

Key information relating to the cash dividend to be paid by Vistin Pharma ASA

Dividend amount (per share): NOK 0.75 Declared currency: NOKLast day including right: 22 January 2024Ex-date: 23 January 2024Record date: 24 January 2024Payment date: 30 January 2024 (on or about)Date of approval: 10 January 2024 For further information, please contact:Alexander Karlsen CFO+47 97 05 36 21 alexander.karlsen@vistin.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act...
Nasdaq GlobeNewswire
11/01/2024

Vistin Pharma ASA: Dividend of NOK 0.75 per share

Norwegian pharmaceutical company Vistin Pharma ASA (“Vistin Pharma”) announced today that the Board has decided for a dividend of NOK 0.75 per share. The dividend is according to the power of attorney given by the annual general meeting on the 22 ndof May 2023.Dividend will be distributed as a repayment of paid-in capital (share premium).For further information, please contact:Alexander Karlsen CFO +47 97 05 36 21alexander.karlsen@vistin.comThis information is subject to the...
Nasdaq GlobeNewswire
11/01/2024

SHL Medical further strengthens vertical capabilities with the acquisition of US…

With two new manufacturing sites underway in North Charleston, SC, USA, and Zug, Switzerland, complementing the existing facilities in Taiwan, SHL strategically addresses the growing demand in the autoinjector market. Superior Tooling will support SHL's strategic manufacturing operations globally, especially strengthening its vertical capabilities for the new site in North Charleston, while solidifying its local presence. This expansion of strengths underlines SHL's global strategy, emphasizing…
PR Newswire
11/01/2024

Intraoperative Neuromonitoring Market to Reach $8.7 Billion, Globally, by 2032…

Request Sample of the Report on Intraoperative Neuromonitoring Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/1920 Request Sample of the Report on Intraoperative Neuromonitoring Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/1920 Prime determinants of growth Growing healthcare infrastructure, rise in prevalence of chronic conditions that require accurate monitoring, and growing awareness regarding the use of intraoperative...
PR Newswire
11/01/2024

AIRS Medical Receives EU Medical Device Regulation CE Certification for SwiftMR™

AIRS Medical, by obtaining its initial certification under MDR instead of MDD, has demonstrated adherence to stringent European standards for product performance, safety, and quality. Following FDA 510(k) expanded approval in October 2023, obtaining MDR CE certification is a notably swift pace in the AI medical device industry. AIRS Medical, by obtaining its initial certification under MDR instead of MDD, has demonstrated adherence to stringent European standards for product performance,...
PR Newswire
11/01/2024

The European Medicines Agency's Scientific Advisory Group (SAG) to discuss the…

Eisai expects the European Commission's decision for the MAA of lecanemab in the second quarter of 2024, if the opinion from the CHMP is received by March 31, 2024, following discussion by the SAG. Eisai expects the European Commission's decision for the MAA of lecanemab in the second quarter of 2024, if the opinion from the CHMP is received byMarch 31, 2024, following discussion by the SAG. Eisai serves as the lead of Leqembi development and regulatory submissions globally with both...
PR Newswire
11/01/2024

Collagen Market worth $7.4 billion by 2030 - Exclusive Report by…

Browse in-depth TOC on "Collagen Market" Browse in-depth TOC on "Collagen Market" 339 – Tables 72 – Figures 337 – Pages The marine segment in the collagen market is poised for remarkable growth with the highest CAGR in the upcoming forecast period. The marine source of collagen has swiftly emerged as the frontrunner in the collagen market, experiencing unparalleled growth for several compelling reasons. Its sustainability, derived from fish by-products that minimize...
PR Newswire
11/01/2024

Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032…

Key Takeaways from the Focal Segmental Glomerulosclerosis Market Report Key Takeaways from the Focal Segmental Glomerulosclerosis Market Report Discover which therapies are expected to grab the major FSGS market share @Focal Segmental Glomerulosclerosis Market Report Focal Segmental Glomerulosclerosis Overview Focal segmental glomerulosclerosis (FSGS) is a distinct histological pattern of damage characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of...
PR Newswire
10/01/2024

Press release Biocartis Group NV: Disclosure of transparency notification…

BIOCARTIS GROUP NV (Euronext Brussels: BCART)PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification(Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings) 1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, showing that JPMorgan Chase & Co., with registered office at c/o CT Corporation, 1209 Orange Street, Wilmington, DE19801, USA,...
Nasdaq GlobeNewswire
10/01/2024

Press release Biocartis Group NV: Disclosure of transparency notification…

BIOCARTIS GROUP NV (Euronext Brussels: BCART)PRESS RELEASE - REGULATED INFORMATION - 10 January 2024, 23:00 CET Disclosure of transparency notification(Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)1. Summary of notice BIOCARTIS GROUP NV received a transparency notification on January 5, 2024, of which an amended version was received on January 8, 2024, showing that Invesco Ltd., with registered office at 1331, Spring Street NW,...
Nasdaq GlobeNewswire
10/01/2024

Inventiva draws down the second tranche of €25 million under existing Finance…

Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH.This second tranche carries an interest rate of 7% annually and has a maturity of 3 years and a repayment in fine which is expected to occur after the anticipated publication of the results of the NATiV3 Phase III trial evaluating lanifibranor in patients with NASH, expected in the first half of 2026.The €25 million supports Inventiva's...
Nasdaq GlobeNewswire
10/01/2024

Groupe Casino: Granting by the Autorité des Marchés Financiers (AMF) of a waiver…

Granting by theAutorité des Marchés Financiers(AMF) of a waiver of the obligation for the members of the Consortium acting in concert (composed of EP Equity Investment III s.à r.l., Fimalac and Attestor) and their investment vehicle (France Retail Holdings) to file a draft public offer for the Casino shares Paris, 10 January 2024Casino announces that on 9 January 2024 theAutorité des Marchés Financiers(the "AMF") granted a waiver of the obligation for the members of the...
Nasdaq GlobeNewswire
10/01/2024

Rising Prevalence of Cancer to Steer Peripherally Inserted Central Catheter…

Request Exclusive Sample Report: Peripherally Inserted Central Catheter Market Strategic Insights, https://www.futuremarketinsights.com/reports/sample/rep-gb-12726 Request Exclusive Sample Report: Peripherally Inserted Central Catheter Market Strategic Insights,https://www.futuremarketinsights.com/reports/sample/rep-gb-12726 Peripherally inserted central catheters (PICCs) are in greater demand due to the rising prevalence of cancer. This is because chemotherapy medications are...
PR Newswire
10/01/2024

Report on Carbios' liquidity contract with Natixis ODDO BHF

Shares concerned: Carbios (ISIN code: FR0011648716)Market concerned: Euronext Growth Paris Clermont-Ferrand (France), 10 January 2024 (18:00 CET).CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, reports today about the liquidity contract entrusted to Natixis ODDO BHF.As of December 31, 2023, the following assets appeared on the liquidity account: ...
Nasdaq GlobeNewswire
10/01/2024

WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering…

Dr. Chris Chen, CEO of WuXi Biologics, commented, "Our unique CRDMO model is proven again. We are very pleased to support BioNTech's growing innovative pipeline with antibodies discovered through our leading integrated discovery platforms. This agreement demonstrates our continued recognition as an industry leader in discovery service solutions, and further validates our ability to provide integrated discovery technology platforms for global partners to develop new modalities. We are…
PR Newswire
10/01/2024

Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC

Company announcement – No. 2 / 2024 Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC Copenhagen, Denmark, 10 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 9 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from Avoro Capital Advisors...
Nasdaq GlobeNewswire
10/01/2024
Altri  Comunicati